miRNA-21 promotes cell proliferation and invasion via VHL/PI3K/AKT in papillary thyroid carcinoma

Zang, Chuanshan; Sun, Jian; Liu, Wenyi; Chu, Chunqin; Jiang, Liwei; Ge, Ruifeng

doi:10.1007/s13577-019-00254-4

Cited by 30 publications

(24 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In RCC cells, miR-21 was proposed to act as an oncogenic miRNA and enhance tumor progression and proliferation while inhibiting apoptosis Li X. et al, 2014;Petrozza et al, 2015). Additionally, it may target VHL mRNA (Sun et al, 2019;Zang et al, 2019), the loss of which plays a major role in RCC tumorigenesis and promotes normoxic HIF signaling (Shen and Kaelin, 2013). miR-106a is another candidate for a diagnostic miRNA in ccRCC as it was significantly overexpressed in the serum of 30 ccRCC patients with matched controls and was reduced after curative surgery, which indicates a potential use in post-surgery biomarker monitoring (Tusong et al, 2017).…”

Section: Cssmentioning

confidence: 99%

Circulating Non-coding RNAs in Renal Cell Carcinoma—Pathogenesis and Potential Implications as Clinical Biomarkers

Barth

Drula

Ott

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Liquid biopsy-the determination of circulating cells, proteins, DNA or RNA from biofluids through a "less invasive" approach-has emerged as a novel approach in all cancer entities. Circulating non-(protein) coding RNAs including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and YRNAs can be passively released by tissue or cell damage or actively secreted as cell-free circulating RNAs, bound to lipoproteins or carried by exosomes. In renal cell carcinoma (RCC), a growing body of evidence suggests circulating non-coding RNAs (ncRNAs) such as miRNAs, lncRNAs, and YRNAs as promising and easily accessible blood-based biomarkers for the early diagnosis of RCC as well as for the prediction of prognosis and treatment response. In addition, circulating ncRNAs could also play a role in RCC pathogenesis and progression. This review gives an overview over the current study landscape of circulating ncRNAs and their involvement in RCC pathogenesis as well as their potential utility as future biomarkers in RCC diagnosis and treatment.

show abstract

Section: Cssmentioning

confidence: 99%

Circulating Non-coding RNAs in Renal Cell Carcinoma—Pathogenesis and Potential Implications as Clinical Biomarkers

Barth

Drula

Ott

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…This miRNA has diagnostic value in head and neck cancer as it is released into the bloodstream [26]. miRNA-21 promotes cell proliferation and invasion via the VHL/PI3K/AKT pathway [27]. miRNA-222 and miRNA-221 also have potential to become biomarkers of PTC.…”

Section: Introductionmentioning

confidence: 99%

Plasma-Derived miRNA-222 as a Candidate Marker for Papillary Thyroid Cancer

Kondrotienė

Daukša

Pamedytytė

et al. 2020

IJMS

View full text Add to dashboard Cite

We analyzed five miRNA molecules (miR-221; miR-222; miR-146b; miR-21; miR-181b) in the plasma of patients with papillary thyroid cancer (PTC), nodular goiter (NG) and healthy controls (HC) and evaluated their diagnostic value for differentiation of PTC from NG and HC. Preoperative PTC plasma miRNA expression (n = 49) was compared with plasma miRNA in the HC group (n = 57) and patients with NG (n = 23). It was demonstrated that miR-221; miR-222; miR-146b; miR-21 and miR-181b were overexpressed in preoperative PTC plasma samples compared to HC (p < 0.0001; p < 0.0001; p < 0.0001; p < 0.0001; p < 0.002; respectively). The upregulation in tumor tissue of these miRNAs was consistent with The Cancer Genome Atlas Thyroid Carcinoma dataset. A significant decrease in miR-21; miR-221; miR-146b and miR-181b expression was observed in the plasma of PTC patients after total thyroidectomy (p = 0.004; p = 0.001; p = 0.03; p = 0.036; respectively). The levels of miR-222 were significantly higher in the preoperative PTC compared to the NG group (p = 0.004). ROC curve (receiver operating characteristic curve) analysis revealed miR-222 as a potential marker in distinguishing PTC from NG (AUC 0.711; p = 0.004). In conclusion; circulating miR-222 profiles might be useful in discriminating PTC from NG.

show abstract

“…Beyond that, the association between miR-21 with the clinicopathological characteristics of thyroid cancer uncovered its capability to be used as a prognostic factor. The survival analysis by Zang et al revealed that the higher expression of miR-21 can predict poor prognosis of PTC patients (75). In another study, the multivariate survival analysis of patients for at least 120 months after surgery showed that miR-9 and miR-21 were significant independent prognostic factors for recurrence of PTC patients (191).…”

Section: Ncrnas Playing Role As Prognostic Factors Of Thyroid Cancermentioning

confidence: 97%

“…In this section, we review the recent advances in prognostic ncRNAs in thyroid cancer, that are listed in Table 5. The overexpression and oncogenic actions of miR-21 have been widely reported in thyroid cancer (75,(188)(189)(190), suggesting that this miRNA could be a potential diagnostic factor for early detection of thyroid cancer. Beyond that, the association between miR-21 with the clinicopathological characteristics of thyroid cancer uncovered its capability to be used as a prognostic factor.…”

Section: Ncrnas Playing Role As Prognostic Factors Of Thyroid Cancermentioning

confidence: 99%

“…For instance, miR-21 overexpression was shown to target Von Hippel-Lindau Tumor Suppressor (VHL) and activate PI3K/Akt pathway. This, in turn, resulted in an increase in the EMT markers N-cadherin and vimentin, and promote cell proliferation and invasion (75). PTEN is another validated target of miR-21, reported in various human cancers, that plays pivotal role in the inhibition of PI3K/Akt pathway (76)(77)(78).…”

Section: Pi3k/akt-mediated Tumorigenic Effects Of Dysregulated Mirnasmentioning

confidence: 99%

See 1 more Smart Citation

Non-Coding RNAs: Uncharted Mediators of Thyroid Cancer Pathogenesis

Tabatabaeian¹,

Yang²,

Tay³

2020

Preprint

View full text Add to dashboard Cite

Thyroid cancer is the most prevalent malignancy of the endocrine system and the ninth most common cancer globally. Despite the advances in the management of thyroid cancer, there are critical issues with the diagnosis and treatment of thyroid cancer that result in the poor overall survival of undifferentiated and metastatic thyroid cancer patients. Recent studies have revealed the role of different non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) that are dysregulated during thyroid cancer development or the acquisition of resistance to therapeutics, and may play key roles in treatment failure and poor prognosis of the thyroid cancer patients. Here, we systematically review the emerging roles and molecular mechanisms of ncRNAs that regulate thyroid tumorigenesis and drug response. We then propose the potential clinical implications of ncRNAs as novel diagnostic and prognostic biomarkers for thyroid cancer.

show abstract

miRNA-21 promotes cell proliferation and invasion via VHL/PI3K/AKT in papillary thyroid carcinoma

Cited by 30 publications

References 27 publications

Circulating Non-coding RNAs in Renal Cell Carcinoma—Pathogenesis and Potential Implications as Clinical Biomarkers

Circulating Non-coding RNAs in Renal Cell Carcinoma—Pathogenesis and Potential Implications as Clinical Biomarkers

Plasma-Derived miRNA-222 as a Candidate Marker for Papillary Thyroid Cancer

Non-Coding RNAs: Uncharted Mediators of Thyroid Cancer Pathogenesis

Contact Info

Product

Resources

About